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background: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in those with chronic HIV infection, due in part to 
HIV associated dyslipidemia. An emerging CVD risk factor is triglyceride-rich remnant lipoprotein cholesterol (RLP-C: the sum of IDL and VLDL3 
cholesterol). The effects of statin therapy on lipoprotein subfractions, including RLP-C, in HIV dyslipidemia are unknown.
methods: The INTREPID trial (NCT 01301066) randomized 252 subjects with HIV to pitavastatin 4 mg daily vs. pravastatin 40 mg daily, and 
showed significantly greater LDL-C reduction at 12 weeks with pitavastatin. In post hoc analysis, we measured apolipoproteins AI and B (apoAI, 
apoB) and lipoprotein cholesterol subfractions separated by density gradient ultracentrifugation (Atherotech, Birmingham, AL) at baseline and 12 
weeks. We compared changes in subfractions over 12 weeks using analysis of covariance.
results: Lipoprotein subfraction data were available for 213 subjects (pitavastatin n=104, pravastatin n=109). Baseline characteristics were 
similar. Reductions in RLP-C and ratios of risk (apoB/AI, TC/HDL-C) were significantly greater with pitavastatin (p<0.05, Table). There were no 
differences in changes in HDL-C, HDL-C subfractions or Lp(a)-C levels.
conclusions: In patients with HIV, pitavastatin lowered both RLP-C and established apolipoprotein and lipid risk ratios more so than pravastatin. 
The impact of RLP-C reduction on CVD in HIV dyslipidemic patients merits further study.
